Epidiolex® for Anxiety in Pediatric Epilepsy

ClinicalTrials.gov ID: NCT05324449

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05324449. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Epidiolex® For The Treatment Of Anxiety Comorbidity in Refractory Pediatric Epilepsy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.

Study identification

NCT ID: NCT05324449
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

Cannabidiol 100 MG/ML Drug

Drug

Eligibility (public fields only)

Age range: 6 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 5, 2022 (Actual)
Primary completion: Mar 17, 2025 (Actual)
Completion: May 5, 2025 (Actual)
Last update posted: Jul 2, 2025

2022 – 2025

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Kennedy Krieger Institute	Baltimore	Maryland	21205	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05324449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 2, 2025 · Synced Nov 12, 2026